SMARCA4 and cancer: We have reported that SMARCA4 is required to promote cell growth inhibition triggered by corticoids and retinoids in cancer cells6 and that such effects are enhanced by combination with the pan- histone deacetylase (HDAC) inhibitor suberanilohydroxamic acid (SAHA)20.